Open access
Open access
Powered by Google Translator Translator

M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.

11 Nov, 2022 | 14:04h | UTC

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials – The Lancet


Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD

Related: RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.


Commentary on Twitter

Under a Creative Commons Attribution (CC BY 4.0) License


Stay Updated in Your Specialty

Telegram Channels

WhatsApp alerts 10-day free trial

No spam, just news.